Precigen Inc (PGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precigen Inc (PGEN) has a cash flow conversion efficiency ratio of -1.122x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.46 Million) by net assets ($20.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Precigen Inc balance sheet independence to measure how much of total assets are equity-financed.
Precigen Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Precigen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PGEN cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Precigen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precigen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FAP Agri Tbk PT
JK:FAPA
|
0.099x |
|
Greatech Technology Bhd
KLSE:0208
|
0.011x |
|
Autek China Inc
SHE:300595
|
0.031x |
|
Jinan Acetate Chemical Co Ltd
TW:4763
|
0.051x |
|
Concentrix Corporation
NASDAQ:CNXC
|
-0.030x |
|
LPI Capital Bhd
KLSE:8621
|
0.052x |
|
Star Petroleum Refining Co Ltd
BK:SPRC
|
-0.019x |
|
Mineros SA
TO:MSA
|
0.098x |
Annual Cash Flow Conversion Efficiency for Precigen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Precigen Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Precigen Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.91 Million | $-87.83 Million | -4.200x | -137.28% |
| 2024-12-31 | $38.51 Million | $-68.17 Million | -1.770x | -213.40% |
| 2023-12-31 | $118.50 Million | $-66.93 Million | -0.565x | -9.64% |
| 2022-12-31 | $126.26 Million | $-65.05 Million | -0.515x | +0.84% |
| 2021-12-31 | $107.35 Million | $-55.77 Million | -0.520x | +54.69% |
| 2020-12-31 | $67.17 Million | $-77.02 Million | -1.147x | -6.75% |
| 2019-12-31 | $71.71 Million | $-77.02 Million | -1.074x | -227.40% |
| 2018-12-31 | $378.72 Million | $-124.24 Million | -0.328x | -72.17% |
| 2017-12-31 | $546.54 Million | $-104.14 Million | -0.191x | -93.77% |
| 2016-12-31 | $569.25 Million | $-55.98 Million | -0.098x | -294.32% |
| 2015-12-31 | $704.89 Million | $35.67 Million | 0.051x | +204.30% |
| 2014-12-31 | $409.29 Million | $-19.86 Million | -0.049x | +65.53% |
| 2013-12-31 | $381.34 Million | $-53.68 Million | -0.141x | -173.57% |
| 2012-12-31 | $-321.55 Million | $-61.53 Million | 0.191x | -48.22% |
| 2011-12-31 | $-221.26 Million | $-81.76 Million | 0.370x | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more